These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27207344)

  • 1. Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors.
    Watrowski R; Heinze G; Jäger C; Forster J; Zeillinger R
    Tumour Biol; 2016 Sep; 37(9):12079-12087. PubMed ID: 27207344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simple laboratory score improves the preoperative diagnosis of adnexal mass.
    Watrowski R; Zeillinger R
    Tumour Biol; 2016 Apr; 37(4):4343-9. PubMed ID: 26499778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEA in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
    Sagi-Dain L; Lavie O; Auslander R; Sagi S
    Int J Biol Markers; 2015 Nov; 30(4):e394-400. PubMed ID: 26109367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay.
    Bristow RE; Smith A; Zhang Z; Chan DW; Crutcher G; Fung ET; Munroe DG
    Gynecol Oncol; 2013 Feb; 128(2):252-9. PubMed ID: 23178277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Value of the Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Thrombocytosis in the Preoperative Investigation of Ovarian Masses.
    Yoshida A; Sarian LO; Marangoni M; Firmano IC; Derchain SF
    Rev Bras Ginecol Obstet; 2020 Jul; 42(7):397-403. PubMed ID: 32559800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass: Retrospective Cohort Study and Review of the Literature.
    Sagi-Dain L; Lavie O; Auslander R; Sagi S
    Am J Clin Oncol; 2018 Sep; 41(9):838-844. PubMed ID: 28338481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of thrombocytosis and high CA 125 level in women with adnexal masses.
    Atacag T
    Eur J Gynaecol Oncol; 2012; 33(5):517-20. PubMed ID: 23185800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of malignancy index in discrimination of adnexal masses.
    Ulusoy S; Akbayir O; Numanoglu C; Ulusoy N; Odabas E; Gulkilik A
    Int J Gynaecol Obstet; 2007 Mar; 96(3):186-91. PubMed ID: 17280665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
    Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
    J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
    Bozkurt M; Yumru AE; Aral I
    Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
    Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
    Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses.
    Xie WT; Wang YQ; Xiang ZS; Du ZS; Huang SX; Chen YJ; Tang LN
    J Ovarian Res; 2022 Jan; 15(1):15. PubMed ID: 35067220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of risk of malignancy indices; RMI 1-4 in borderline ovarian tumor.
    Yenen MC; Alanbay I; Aktürk E; Ercan CM; Coksuer H; Karaşahin E; Ozan H; Dede M
    Eur J Gynaecol Oncol; 2012; 33(2):168-73. PubMed ID: 22611957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses.
    Zheng H; Tie Y; Wang X; Yang Y; Wei X; Zhao X
    Medicine (Baltimore); 2019 Feb; 98(7):e14577. PubMed ID: 30762809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive role of thrombocytosis in benign, borderline and malignant ovarian tumors.
    Abdulrahman GO; Das N; Lutchman Singh K
    Platelets; 2020 Aug; 31(6):795-800. PubMed ID: 31665945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-operative prediction of serum CA125 level in women with ovarian masses.
    Benjapibal M; Neungton C
    J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses.
    Andersen ES; Knudsen A; Rix P; Johansen B
    Gynecol Oncol; 2003 Jul; 90(1):109-12. PubMed ID: 12821350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.